Last reviewed · How we verify
Polatuzumab Vedotin, Rituximab, Lenalidomide
Monoclonal antibody targeting CD19, conjugated with microtubule inhibitor
Monoclonal antibody targeting CD19, conjugated with microtubule inhibitor Used for Diffuse large B-cell lymphoma, Follicular lymphoma.
At a glance
| Generic name | Polatuzumab Vedotin, Rituximab, Lenalidomide |
|---|---|
| Sponsor | Yan Zhang, MD |
| Drug class | Monoclonal antibody-drug conjugate |
| Target | CD19 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Polatuzumab vedotin is a monoclonal antibody-drug conjugate that targets CD19 on B cells and delivers a microtubule inhibitor to induce cell death.
Approved indications
- Diffuse large B-cell lymphoma
- Follicular lymphoma
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea
Key clinical trials
- A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma (PHASE2)
- Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL (PHASE2)
- Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) (PHASE1, PHASE2)
- Pola-ZR2P in Previously Untreated DLBCL (PHASE2)
- Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma (PHASE2)
- The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma (PHASE3)
- A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL (PHASE2)
- Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: